U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07616336) titled 'Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic Syndromes' on Jan. 17.
Brief Summary: Myelodysplastic syndromes (MDS) are a group of bone marrow disorders that can cause low blood cell counts and may progress to acute leukemia. Treatment options for patients with intermediate-to-high-risk MDS are limited, especially for older patients or those who are not suitable for intensive chemotherapy or hypomethylating agents.
Chidamide is an oral histone deacetylase inhibitor that has shown antitumor activity in several hematologic malignancies. This study aims to evaluate the effectiveness and safety of chidamide used al...